

31st August, 2015

Ms. Dhara Barot
Assistant Manager – Listing Compliance
BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001

Dear Madam,

Security Code: 532300

Sub: Clarification on news item appearing in Mint

We refer to your E-mail dated 31st August, 2015 regarding news item in the Mint captioned “Wockhardt recall drugs from US”.

This is to inform you that the Company has earlier decided to recall, as a part of remedial measure the remaining batches in the US market that were manufactured prior to US FDA Import Alerts even though there was no evidence of risk to patient safety from these products. The same was informed to the Stock Exchanges on 28th April, 2015 by the Company. (Acknowledged copy of the letter is enclosed for reference). The recall stated in the news item forms part of the same.

As a part of standard practice, the Company has to inform to US FDA periodically the products actually received from the trade against such recall. Such periodic returns of products are reported by the media based on such information submitted to US FDA by the Company from time to time even though they are not additional recalls.

The Company has policy to recognise and provide in the books of accounts such recalls and accordingly the same has been duly recognised in the published financial results of the Company. The impact on the revenue from any future returns of the products is not expected to be significant.

The Company keeps the exchange informed about events, information etc. including price sensitive information in accordance with regulatory requirements. In present case, we do not have any important information / announcement to be shared.

In the event that there is any development that requires disclosure under Clause 36 of the Listing Agreement, we will make the same in accordance with the regulatory requirements.

This is for your information and records.

For **Wockhardt Limited**



Narendra Singh
Company Secretary

Encl: As above

April 28, 2015

Bombay Stock Exchange Limited
Corporate Relations Department
P J Towers, Dalal Street
Mumbai 400 001

Fax No. 022- 26598237 / 38

Scrip Code: 532300

Dear Sir,

During the last US FDA cGMP inspection of the facilities at L1- Chikalthana and Waluj in Aurangabad, Maharashtra, some observations were reported pertaining to batches of some products manufactured prior to the US FDA Import Alerts.

Whereas the Company continues to supply some of the products in the US market manufactured in the same facilities, several batches of other products, manufactured prior to the Import Alerts may still be in the US market.

As a measure of preparedness and as an abundant precaution, the Company has now decided to recall, as a part of remedial measure all the remaining batches in the US market that were manufactured prior to the US FDA Import Alerts even though there is no evidence of risk to patient safety from the products currently available in the US market.

Additionally, the MHRA, UK has restored the EU GMP certification of our potent product facility at Kadaiya, Daman.

As per clause 36 of the Listing Agreement the company keeps the exchange informed about events, information etc. including price sensitive information in accordance with regulatory requirement.

This is for your information and record.

Yours Cordially,

For **Wockhardt Limited**



Amruta Avasare
Assistant Company Secretary